Market Cap | 12.29M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.62M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 5.00% |
Sales | 449.62k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | 3.22 | EPS next 5Y | - | 52W High Chg | -72.00% |
Recommedations | 2.00 | Quick Ratio | 8.63 | Shares Outstanding | 7.04M | 52W Low Chg | 27.00% |
Insider Own | 45.56% | ROA | -62.27% | Shares Float | 3.77M | Beta | - |
Inst Own | 5.48% | ROE | -118.13% | Shares Shorted/Prior | 45.66K/53.08K | Price | 2.14 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 9,643 | Target Price | 2.00 |
Oper. Margin | -603.76% | Earnings Date | - | Volume | 6,432 | Change | 1.90% |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Maxim Group | Buy | Apr 9, 24 |